03/13/2025
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
03/09/2025
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
03/07/2025
3:43 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form POS AM | |
02/27/2025
3:23 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
02/27/2025
3:23 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
02/27/2025
3:13 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/27/2025
3:02 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/14/2025
5:06 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
02/14/2025
8:00 AM | RTW INVESTMENTS, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
01/14/2025
4:16 PM | HENDERSON MICHAEL THOMAS (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
7:08 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for SYRE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
11/19/2024
4:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/18/2024
4:10 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B5 | |
11/14/2024
4:50 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
3:33 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:44 AM | Deep Track Capital, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:35 AM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/12/2024
9:34 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
3:53 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/28/2024
3:41 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/25/2024
3:28 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
1:10 PM | Deutsch Peter E. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/15/2024
5:10 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/02/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
10/01/2024
5:26 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/01/2024
5:34 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:04 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/07/2024
8:12 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
08/07/2024
3:17 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/10/2024
8:48 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
05/30/2024
3:33 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:40 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:08 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/29/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/25/2024
3:40 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
04/25/2024
3:55 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/23/2024
5:22 PM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
04/18/2024
7:24 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
Elon Warns: Exec Order 14024 Targets Dollar (Ad) Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement.
When the dollar collapses, your savings could disappear overnight.
With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar. Go Here to Learn What's Happening and How to Prepare >> |
